Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 101

1.

Antigenic conservation and immunogenicity of the HIV coreceptor binding site.

Decker JM, Bibollet-Ruche F, Wei X, Wang S, Levy DN, Wang W, Delaporte E, Peeters M, Derdeyn CA, Allen S, Hunter E, Saag MS, Hoxie JA, Hahn BH, Kwong PD, Robinson JE, Shaw GM.

J Exp Med. 2005 May 2;201(9):1407-19.

2.

Construction and phenotypic characterization of HIV type 1 functional envelope clones of subtypes G and F.

Revilla A, Delgado E, Christian EC, Dalrymple J, Vega Y, Carrera C, González-Galeano M, Ocampo A, de Castro RO, Lezaún MJ, Rodríguez R, Mariño A, Ordóñez P, Cilla G, Cisterna R, Santamaría JM, Prieto S, Rakhmanova A, Vinogradova A, Ríos M, Pérez-Álvarez L, Nájera R, Montefiori DC, Seaman MS, Thomson MM.

AIDS Res Hum Retroviruses. 2011 Aug;27(8):889-901. doi: 10.1089/AID.2010.0177. Epub 2011 Feb 16.

PMID:
21226626
4.

Broad and potent neutralizing antibody responses elicited in natural HIV-2 infection.

Kong R, Li H, Bibollet-Ruche F, Decker JM, Zheng NN, Gottlieb GS, Kiviat NB, Sow PS, Georgiev I, Hahn BH, Kwong PD, Robinson JE, Shaw GM.

J Virol. 2012 Jan;86(2):947-60. doi: 10.1128/JVI.06155-11. Epub 2011 Oct 26.

5.

Characterization of CD4-induced epitopes on the HIV type 1 gp120 envelope glycoprotein recognized by neutralizing human monoclonal antibodies.

Xiang SH, Doka N, Choudhary RK, Sodroski J, Robinson JE.

AIDS Res Hum Retroviruses. 2002 Nov 1;18(16):1207-17.

PMID:
12487827
6.

Human immunodeficiency virus type 2 (HIV-2)/HIV-1 envelope chimeras detect high titers of broadly reactive HIV-1 V3-specific antibodies in human plasma.

Davis KL, Bibollet-Ruche F, Li H, Decker JM, Kutsch O, Morris L, Salomon A, Pinter A, Hoxie JA, Hahn BH, Kwong PD, Shaw GM.

J Virol. 2009 Feb;83(3):1240-59. doi: 10.1128/JVI.01743-08. Epub 2008 Nov 19.

7.

Strain specificity and binding affinity requirements of neutralizing monoclonal antibodies to the C4 domain of gp120 from human immunodeficiency virus type 1.

Nakamura GR, Byrn R, Wilkes DM, Fox JA, Hobbs MR, Hastings R, Wessling HC, Norcross MA, Fendly BM, Berman PW.

J Virol. 1993 Oct;67(10):6179-91.

8.

Access of antibody molecules to the conserved coreceptor binding site on glycoprotein gp120 is sterically restricted on primary human immunodeficiency virus type 1.

Labrijn AF, Poignard P, Raja A, Zwick MB, Delgado K, Franti M, Binley J, Vivona V, Grundner C, Huang CC, Venturi M, Petropoulos CJ, Wrin T, Dimitrov DS, Robinson J, Kwong PD, Wyatt RT, Sodroski J, Burton DR.

J Virol. 2003 Oct;77(19):10557-65.

9.

HIV-1 subtype A envelope variants from early in infection have variable sensitivity to neutralization and to inhibitors of viral entry.

Blish CA, Nedellec R, Mandaliya K, Mosier DE, Overbaugh J.

AIDS. 2007 Mar 30;21(6):693-702.

PMID:
17413690
10.
11.

Structural mimicry of CD4 by a cross-reactive HIV-1 neutralizing antibody with CDR-H2 and H3 containing unique motifs.

Prabakaran P, Gan J, Wu YQ, Zhang MY, Dimitrov DS, Ji X.

J Mol Biol. 2006 Mar 17;357(1):82-99. Epub 2006 Jan 9.

PMID:
16426633
12.

Mechanism of human immunodeficiency virus type 1 resistance to monoclonal antibody B12 that effectively targets the site of CD4 attachment.

Wu X, Zhou T, O'Dell S, Wyatt RT, Kwong PD, Mascola JR.

J Virol. 2009 Nov;83(21):10892-907. doi: 10.1128/JVI.01142-09. Epub 2009 Aug 19.

14.

Characterization of neutralization epitopes of simian immunodeficiency virus (SIV) recognized by rhesus monoclonal antibodies derived from monkeys infected with an attenuated SIV strain.

Cole KS, Alvarez M, Elliott DH, Lam H, Martin E, Chau T, Micken K, Rowles JL, Clements JE, Murphey-Corb M, Montelaro RC, Robinson JE.

Virology. 2001 Nov 10;290(1):59-73.

15.
17.

Relationships between CD4 independence, neutralization sensitivity, and exposure of a CD4-induced epitope in a human immunodeficiency virus type 1 envelope protein.

Edwards TG, Hoffman TL, Baribaud F, Wyss S, LaBranche CC, Romano J, Adkinson J, Sharron M, Hoxie JA, Doms RW.

J Virol. 2001 Jun;75(11):5230-9.

18.

Characterization of neutralizing monoclonal antibodies to linear and conformation-dependent epitopes within the first and second variable domains of human immunodeficiency virus type 1 gp120.

McKeating JA, Shotton C, Cordell J, Graham S, Balfe P, Sullivan N, Charles M, Page M, Bolmstedt A, Olofsson S, et al.

J Virol. 1993 Aug;67(8):4932-44.

19.

Evolution of cross-neutralizing antibody specificities to the CD4-BS and the carbohydrate cloak of the HIV Env in an HIV-1-infected subject.

Mikell I, Stamatatos L.

PLoS One. 2012;7(11):e49610. doi: 10.1371/journal.pone.0049610. Epub 2012 Nov 13.

20.

Differences in the antibody response to human immunodeficiency virus-1 envelope glycoprotein (gp160) in infected laboratory workers and vaccinees.

Pincus SH, Messer KG, Schwartz DH, Lewis GK, Graham BS, Blattner WA, Fisher G.

J Clin Invest. 1993 May;91(5):1987-96.

Supplemental Content

Support Center